Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.

Abstract: Disclosed is a method of determining information regarding the location of energy deposition of an ion beam, in particular a proton beam, in an absorptive medium, in particular in the tissue of a patient undergoing radiation therapy, comprising the following steps: generating an intensity modulated ion beam, wherein the intensity modulation comprises one or more modulation frequency components, detecting an acoustic signal attributable to the time dependent energy deposition in said absorptive medium by said intensity modulated ion beam using at least one detection apparatus, said detection apparatus being preferably configured for extracting at least one modulation frequency component of the acoustic signal corresponding to a respective one of the one or more modulation frequency components of said intensity modulation, or a harmonic thereof, and deriving information regarding the location of the energy deposition based, at least in part, on a time lag between the timing of the intensity modulation of sai

Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

Abstract: The present invention relates to a binding molecule having a binding site within the ectodomain of the triggering receptor expressed on myeloid cells 2 (TREM2), wherein the binding molecule inhibits TREM2 cleavage. Said binding molecule is particularly useful for treating and/or preventing a neurological disorder, such as a neurodegenerative disorder. Also encompassed by the present invention is a pharmaceutical composition for use in treating and/or preventing a neurological disorder, wherein the pharmaceutical composition comprises the binding molecule of the present invention. Neurodegenerative disorders that may be treated and/or prevented by using the binding molecule of the present invention include Alzheimer's disease (AD), Frontotemporal lobar degeneration (FTLD), FTLD-like syndrome, Parkinson's disease, Nasu-Hakola disease, Multiple sclerosis (MS), Huntington disease, immune-mediated neuropathies, or Amyotrophic lateral sclerosis (ALS).

Abstract: A method for investigating one or a plurality of phase objects is described, in which a grid made up of elements is used, which is illuminated with light of a light source, the coherence length of which is larger than the average spacing of adjacent elements of the grid. A diffraction image of the illuminating light scattered on the grid is generated, whereby the one or the plurality of phase objects are placed in the light path between the light source and the grid and/or in the light path of the illuminating light scattered on the grid. At least a part of the diffraction image is detected by an optical sensor directly or after interaction with further optical components and converted into a signal. The signal is analyzed further in order to ascertain information relating to the one or plurality of phase objects therefrom. A corresponding device is likewise described.

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

Abstract: Described is a system for inducing and detecting multi-photon processes, in particular multi-photon fluorescence or higher harmonic generation in a sample. The system comprises a dynamically-controllable light source, said dynamically-controllable light source comprising a first sub-light source, said first sub-light source being electrically controllable such as to generate controllable time-dependent intensity patterns of light having a first wavelength, and at least one optical amplifier, thereby allowing for active time-control of creation of multi-photon-excitation. The system further comprises a beam delivery unit for delivering light generated by said dynamically-controllable light source to a sample site, and a detector unit or detector assembly for detecting signals indicative of said multi-photon process, in particular multi-photon fluorescence signals or higher harmonics signals.

Abstract: A swept source OCT system and related method are disclosed. The system comprises a control device for operating a tunable light source in response to an electronic sweep control signal such that the tunable light source carries out wave length sweeps with a repetition rate fsweep, which depends on the frequency of the sweep control signal. The system further comprises a detection device for the time-resolved detection of an interference signal from a sample beam and a reference beam with the help of a detection cycle signal. The sweep control signal and the detection cycle signal are phase-locked, or means for creating a signal or signal sequence are provided, said signal or signal sequence being characterising for the frequency relationship and/or the relative phase position of the sweep control signal and detection cycle signal.

Abstract: The present invention relates to compounds acting as selective inhibitors of CD40-TRAF6 interaction, their use as medicaments and their use in the treatment of (chronic) inflammatory diseases. The present invention also relates to pharmaceutical compositions comprising these compounds.

Abstract: At least one embodiment of the method is designed to create a two-dimensional image of a three-dimensional sample.

Abstract: Compounds, methods of making the compounds and methods of using the compounds are generally described herein. The compounds are generally of formula R1R2N—ZnY LiY, wherein R1 and R2 are independently selected from H, aryl, heteroaryl containing one or more heteroatoms, alkyl, alkenyl, alkynyl, and silicon derivatives thereof; and each Y is independently selected from F, Cl, Br, I, CN, SCN, NCO, HalO3, HalO4, NO3, BF4, PF6, H, an alcoholate of formula OR5, a carboxylate of formula R5CO2; a thiolate of formula SR5, R5P(O)O2, SCOR5, SCSR5, OnSR5 and NOn, wherein n=2 or 3; wherein R5 is selected from substituted or unsubstituted aryls or heteroaryls containing 3 to 24 carbon atoms and one or more heteroatoms selected from B, O, N, S, Se, P, linear, branched or cyclic, substituted or unsubstituted alkyls, alkenyls, alkynyls or H; and wherein Hal is a halogen selected from Cl, Br and I.

Abstract: The present invention relates to a method of identifying a target antigen of T cells comprising (a) contacting (aa) cells expressing (i) a functional T cell receptor complex comprising predefined matching T cell receptor ? and ? chains; and (ii) a read-out system for T cell activation; with (ab) antigen-presenting cells carrying (iii) peptide libraries encoded by randomised nucleic acid sequences; and (iv) MHC molecules recognised by the T cell receptor of (i); (b) assessing T cell activation using said read-out system; (c) isolating antigen-presenting cells that are in contact with the cells in which the read-out system indicates T cell activation; (d) identifying the target antigen or the nucleic acid molecule encoding said target antigen.

Abstract: Disclosed herein is a system (10) for measuring light induced transmission or reflection changes, in particular due to stimulated Raman emission. The system comprises a first light source (12) for generating a first light signal having a first wavelength, a second light source (14) for generating a second light signal having a second wavelength, an optical assembly (16) for superposing said first and second light signals at a sample location (18), and a detection means (24) for detecting a transmitted or reflected light signal, in particular a stimulated Raman signal caused by a Raman-active medium when located at said sample location. Here in at least one of the first and second light sources (12, 14) is one or both of actively controllable to emit a time controlled light pattern or operated substantially in CW mode and provided with an extra cavity modulation means (64) for generating a time controlled light pattern.

Abstract: The invention concerns a new class of tubulin polymerisation inhibitors and their applications in research and medicine, notably in chemotherapy. The invention proposes new azoaryl derivatives of formula (I): as defined in Claim 1, which may be fully reversibly interconverted between non-tubulin-binding trans and tubulin-binding as isomeric forms, either by irradiation or spontaneously.

Abstract: The present invention relates to specific beta-lactone compounds and compositions thereof for the treatment of infections, such as, e.g., infections with bacteria or infections with protozoa, in particular infections with Gram-positive and/or Gram-negative bacteria and of infectious diseases caused by or related to Gram-positive and/or Gram-negative bacteria, and to the modulation of virulence of Gram-positive and/or Gram-negative bacteria or of protozoa by specific beta-lactone compounds. The invention further relates to the use of the compounds or compositions for preventing or eliminating biofilms.

Abstract: Disclosed herein is a coherent dynamically controllable narrow band light source (10), comprising a first sub-light source (12), said first sub-light source being electrically controllable such as to generate controllable time-dependent intensity patterns of light having a first wavelength, a Raman active medium (30) suitable to cause Raman scattering of light having said first wavelength, a second sub-light source (20) capable of emitting light with a second wavelength, said second wavelength being longer than said first wavelength, and an optical fiber or wave guide, wherein said light emitted by said first and second sub-light sources traverses a length of said optical fiber (30) or wave guide in a feed-forward configuration to facilitate a non-linear wavelength conversion step involving said Raman-active medium. At least one of said first and second sub-light sources (12, 20) has a coherence length longer than 0.05 mm, preferably longer than 0.5 mm and most preferably longer than 2 mm.

Abstract: The invention relates to 3,3?-dinitro-5,5?-bis-triazole-1,1?-diol and to salts thereof, and to an energetic active mass comprising said salts.

Abstract: The present invention relates to compounds acting as selective inhibitors of CD40-TRAF6 interaction, their use as medicaments and their use in the treatment of (chronic) inflammatory diseases. The present invention also relates to pharmaceutical compositions comprising these compounds.